

In the Claims:

Kindly cancel claims 1, 3-7, 9-12 and 17 without prejudice.

Kindly amend claim 15 as follows.

C16
15. (Amended) A method for preventing or treating an allergy or a disease of allergic origin, which comprises administering the compound according to claim 18, to a patient in need thereof. Sub F/b

Please add the following new claims.

Sub D1
C17
18. An isolated compound for preventing or treating an allergy, said compound consisting of (a) at least one allergen antigenic determinant which is recognised by a B cell or an antibody secreted by a B cell of a non-atopic individual to said allergen and (b) at least one antigenic determinant of an antigen different from said allergen which triggers T cell activation.

19. The compound according to claim 18, wherein said allergen antigenic determinant is not recognised by a T cell.

20. The compound according to claim 18, wherein the allergen is selected from the group consisting of (a) *Der pI* and *Der pII* of house dust mite *Dermatophagoides pteronyssinus*, (b) the major antigen of *Aspergillus fumigatus*, (c) the staphylococcal B enterotoxin (SEB) and (d) the bovine β -lactoglobulin.

C10
between amino acid 11 and 24, as well as in between amino acid 22 and 34. The 7-39 region of Der pII therefore contains two binding sites for IgG non-atopic individuals.

Page 25, replace the paragraph beginning at line 21 with the following paragraph:

C11
The compound of the invention can be prepared by recombinant cDNA technology to produce a polypeptide made of a series of repetitive units of T and B cell epitope-containing peptides. A polypeptide made of a duplicated T cell epitope derived from TT (amino acids 830 to 844 of the heavy chain) and six repetitive B cell epitopes derived from Der pII is produced by DNA technology. A sequence of two amino acid residues is inserted between each epitope. The sequence is: D - (QYIKANSKFIGITELX)₂ - (CHGSEPCIIHRGKPFX)₅ - (CHGSEPCIIHRGKPFSR, (SEQ ID NO. 3), in which X is GG or SS.

Page 29, replace the paragraph beginning at line 13 with the following paragraph:

C12
Thus, a 32 amino-acid long peptide of sequence QYIKANSKFIGITELGGCHGSEPCNIHRGKPF (sequence ID No. 5) is produced by synthesis as in Example 1. This peptide corresponds to a T cell epitope derived from TT (amino acid 830 to 844) and a B cell epitope derived from Der pII separated by a stretch of GG. The B cell epitope sequence has a point substitution in position 28, i.e. a substitution of I to N, which was shown to eliminate a major T cell epitope by assay systems as described in Figure 5.

replace the paragraph beginning at line 23 with the following paragraph:

C13
The peptide is used for mouse immunization. Thus, six BALB/c mice are injected in each footpad with 50 µl of an emulsion containing 50 µg of the peptide in complete Freund's adjuvant. The same injection procedure is used twice at a fortnight interval, except for the use of

C13
incomplete Freund's adjuvant. Two weeks after the last injection, the mice are bled and the serum shown to contain specific antibodies to the Der pII B cell epitope included in the synthetic peptide used for immunization, and to full-length Der pII protein. Regional draining lymph nodes are obtained for the preparation of T cell suspension. The latter are shown to proliferate in the presence of TT, but not in the presence of Der pII or the peptide corresponding to the B cell moiety used for immunization.

Page 30, replace the paragraph beginning at line 31 with the following paragraph:

C14
The substituted branched peptide is used to immunize BALB/c mice by the same procedure as described in Example 5. The serum is shown to contain antibodies to full-length Der pII and Der pI proteins and to the two B cell epitopes derived from these two allergens. T cell proliferation assays show a positive response to TT and to the influenza A viral protein containing the T cell epitope sequence.

Page 31, replace the paragraph beginning at line 28 with the following paragraph:

C15
 10^7 pfus are administered by inhalation in BALB/c mice. Mice are bled three weeks after and the level of antibodies towards Der p II, and the B cell moiety contained in the immunizing construct is evaluated by direct binding ELISA as in Figure 3.

In the Abstract:

Delete line 21 in its entirety.